Literature DB >> 8246142

Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier.

W A Banks1, A J Kastin, G Komaki, A Arimura.   

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is a newly discovered regulatory peptide related to vasoactive intestinal peptide and is found widely distributed throughout peripheral tissues and the central nervous system. We examined the ability of its two major forms of 38 (P38) and 27 (P27) amino acid residues to cross the murine blood-brain barrier. After i.v. injection, [125I]P27 had a unidirectional influx constant (Ki) into the brain of 2.13 (10(-3)) ml/g/min with no saturable component to entry. Despite being larger and less lipophilic, [125I]P38 entered the brain more than 30% faster by a saturable transport system. A peptide-T analog related to PACAP that has its own saturable transport system did not inhibit the entry of [125I]P38, but did alter its binding to vascular receptors. Despite the greater Ki of [125I]P38, a larger percentage of the i.v. dose of [125I]P27 entered the brain due to favorable pharmacokinetics. However, [125I]P38 was more resistant to degradation within the brain and, after correction for degradation, its Ki increased to 16.5 (10(-3)) ml/g/min. The influences of peripheral degradation and sequestration by capillaries were negated by use of the brain perfusion and capillary depletion methods. These showed that the Ki into the brain interstitial fluid/parenchymal space for [125I]P38 was 15.3 (10(-3)) ml/g/min and was again inhibited with unlabeled P38. Both PACAPs were transported out of the central nervous system and inhibited the efflux of the other, but there was a [125I]P38 preferring subcomponent to the transport system.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8246142

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  42 in total

1.  Transport of an antifungal trypsin inhibitor isolated from corn across the blood-brain barrier.

Authors:  William A Banks; Michael L Niehoff; Robert L Brown; Zhi-Yuan Chen; Thomas E Cleveland
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins.

Authors:  Naoko Nonaka; Susan A Farr; Tomoya Nakamachi; John E Morley; Masanori Nakamura; Seiji Shioda; William A Banks
Journal:  Peptides       Date:  2012-06-09       Impact factor: 3.750

Review 3.  Concepts for biologically active peptides.

Authors:  Abba J Kastin; Weihong Pan
Journal:  Curr Pharm Des       Date:  2010-10       Impact factor: 3.116

4.  Transport of prion protein across the blood-brain barrier.

Authors:  W A Banks; Sandra M Robinson; R Diaz-Espinoza; A Urayama; C Soto
Journal:  Exp Neurol       Date:  2009-05-05       Impact factor: 5.330

Review 5.  Blood-brain barrier and feeding: regulatory roles of saturable transport systems for ingestive peptides.

Authors:  Abba J Kastin; Weihong Pan
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 6.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 7.  Penetration of the blood-brain barrier by peripheral neuropeptides: new approaches to enhancing transport and endogenous expression.

Authors:  M R Lee; R D Jayant
Journal:  Cell Tissue Res       Date:  2018-12-10       Impact factor: 5.249

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

9.  Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6.

Authors:  Hirokazu Ohtaki; Tomoya Nakamachi; Kenji Dohi; Yoichi Aizawa; Atsushi Takaki; Kei Hodoyama; Sachiko Yofu; Hitoshi Hashimoto; Norihito Shintani; Akemichi Baba; Manfred Kopf; Yoichiro Iwakura; Kouhei Matsuda; Akira Arimura; Seiji Shioda
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

Review 10.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.